de Luna D, Tejada RGF, Mena LAJ, Díaz GJ, Lisbette AO, Acevedo N, Calo VS

Language: English
References: 32
Page:
PDF size: 387.45 Kb.

ABSTRACT

Introduction: Antimicrobial resistance is a global concern since infections by resistant pathogens are associated with higher mortality and morbidity.
Objective: To assess the prevalence of Escherichia coli isolates producing extended-spectrum and AmpC beta-lactamase (ESBL) in urine samples from patients at the Hospital Metropolitano de Santiago in Dominican Republic.
Methods: Pathogen identification and antibiogram were carried out by the automated systems BD Phoenix or Microscan®. General information and past medical history were gathered from patients with a positive urine culture for E. coli. Manual ESBL/AmpC screening was performed with the commercial ESBL+AmpC screen disc kit from Liofilchem Laboratory, Italy.
Results: One or both of the studied phenotypes were present in 36% of the analyzed isolates. Among the risk factors for the detection of E. coli producing ESBL and/or AmpC in urine were male gender, advanced age, placement of urinary catheter, arterial hypertension, neoplasms, and coexistence of two or more comorbidities. Apart from cephalosporins resistance, isolates producing ESBL and/or AmpC also showed higher resistance to other antibiotics, such as gentamicin (66.7%), ciprofloxacin and levofloxacin (83.3%), and ampicillin (91.7%). Furthermore, 85% of the ESBL/AmpC producing samples were multidrug resistant (resistant to 1 or more drugs in at least 3 different antibiotic categories).
Conclusions: The high prevalence of antimicrobial resistance found in this study highlights the importance of implementing national and global measures to tackle the problem, especially in developing countries such as the Dominican Republic, where resources are scarce.

REFERENCES

1. Foxman B. Urinary tract infection syndromes. Occurrence, recurrence, bacteriology, risk factors, and disease burden. Infect Dis Clin North Am. 2014;28(1):1-13.

2. Schappert SM, Rechtsteiner EA. Ambulatory medical care utilization estimates for 2007. Vital Health Stat. 2011;13(169):1-38.

3. Klein RD, Hultgren SJ. Urinary tract infections: microbial pathogenesis, host-pathogen interactions and new treatment strategies. Nat Rev Microbiol. 2020;18(4):211-6.

4. O&apos ; Neil J. Tackling drug-resistant infections globally: final report and recommendations. In: Ro A, ed. Resistance. London, United Kingdom; 2016. p. 1, 84.

5. World Health Organization. Antimicrobial resistance. Global report on surveillance. World Heal Organ; 2014.

6. Paterson DL, Bonomo RA. Extended-spectrum ß-lactamases: A clinical update. Clin Microbiol Rev. 2005;18(4):657-86.

7. Tamma PD, Doi Y, Bonomo RA, Johnson JK, Simner PJ. A Primer on AmpC ß-lactamases: necessary knowledge for an increasingly multidrug-resistant world. Clin Infect Dis. 2019;69(8):1446-55.

8. Padmavathy K, Padma K, Rajasekaran S. Extended-spectrum ß-lactamase/AmpC-producing uropathogenic Escherichia coli from HIV patients: Do they have a low virulence score? J Med Microbiol. 2013;62(Pt 3):345-51.

9. Jacoby GA. AmpC beta-lactamases. Clin Microbiol Rev. 2009;22(1):161-82.

10. Rogers BA, Sidjabat HE, Paterson DL. Escherichia coli O25b-ST131: A pandemic, multiresistant, community-associated strain. J Antimicrob Chemother. 2011;66(1):1-14.

11. Albaramki JH, Abdelghani T, Dalaeen A, Khdair Ahmad F, Alassaf A, Odeh R, et al. Urinary tract infection caused by extended-spectrum ß-lactamase-producing bacteria: Risk factors and antibiotic resistance. Pediatr Int. 2019;61(11):1127-32.

12. Yang YS, Ku CH, Lin JC, Shang ST, Chiu CH, Yeh KM, et al. Impact of extended-spectrum ß-lactamase-producing Escherichia coli and Klebsiella pneumoniae on the outcome of community-onset bacteremic urinary tract infections. J Microbiol Immunol Infect. 2010;43(3):194-9.

13. Magruder M, Sholi AN, Gong C, Zhang L, Edusei E, Huang J, et al. Gut uropathogen abundance is a risk factor for development of bacteriuria and urinary tract infection. Nat Commun. 2019;10(1):5521.

14. Karanika S, Karantanos T, Arvanitis M, Grigoras C, Mylonakis E. Fecal colonization with extended-spectrum beta-lactamase-producing Enterobacteriaceae and risk factors among healthy individuals: a systematic review and metaanalysis. Clin Infect Dis. 2016;63(3):310-8.

15. de Luna D, Sánchez JJ, López M, Pérez M del C, Cabán L, Roque Y, et al. Antibiotic resistance profile in intrahospital pediatric services at third level centers in Dominican Republic. Infectio. 2020;24(2):66-70.

16. de Luna D, Sánchez JJ, Peguero M, García W, Liciaga S, Brito F, et al. Antimicrobial resistance profiles of microorganisms isolated from hospitalized patients in Dominican Republic. Rev Panam Salud Publica. 2020;44:e36.

17. Bouassida K, Jaidane M, Bouallegue O, Tlili G, Naija H, Mosbah AT. Nosocomial urinary tract infections caused by extended-spectrum beta-lactamase uropathogens: Prevalence, pathogens, risk factors, and strategies for infection control. Can Urol Assoc J. 2016;10(3-4):E87-93.

18. Albu S, Voidazan S, Bilca D, Badiu M, Truta A, Ciorea M, et al. Bacteriuria and asymptomatic infection in chronic patients with indwelling urinary catheter the incidence of ESBL bacteria. Med (United States). 2018;97(33):e11796.

19. CLSI. Performance standards for antimicrobial susceptibility testing. 27th ed. CLSI supplement M100. Wayne, PA: Clinical and Laboratory Standards Institute; 2017.

20. Bader MS, Loeb M, Brooks AA. An update on the management of urinary tract infections in the era of antimicrobial resistance. Postgrad Med. 2017;129(2):242-58.

21. Castillo-Tokumori F, Irey-Salgado C, Málaga G. Worrisome high frequency of extended-spectrum beta-lactamase-producing Escherichia coli in community-acquired urinary tract infections: a case-control study. Int J Infect Dis. 2017;55:16-9.

22. Pandit R, Awal B, Shrestha SS, Joshi G, Rijal BP, Parajuli NP. Extended-spectrum ß-lactamase (ESBL) genotypes among multidrug-resistant uropathogenic Escherichia coli clinical isolates from a teaching hospital of Nepal. Interdiscip Perspect Infect Dis. 2020;2020:6525826.

23. Alqasim A, Abu Jaffal A, Alyousef AA. Prevalence of multidrug resistance and extended-spectrum ß-Lactamase carriage of clinical uropathogenic Escherichia coli isolates in Riyadh, Saudi Arabia. Int J Microbiol. 2018;2018:3026851.

24. Jena J, Sahoo RK, Debata NK, Subudhi E. Prevalence of TEM, SHV, and CTX-M genes of extended-spectrum ß-lactamase-producing Escherichia coli strains isolated from urinary tract infections in adults. 3 Biotech. 2017;7(4):244.

25. Critchley IA, Cotroneo N, Pucci MJ, Mendes R. The burden of antimicrobial resistance among urinary tract isolates of Escherichia coli in the United States in 2017. PLoS One. 2019;14(12):e0220265.

26. Lee CH, Lee YT, Kung CH, Ku WW, Kuo SC, Chen TL, et al. Risk factors of community-onset urinary tract infections caused by plasmid-mediated AmpC ß-lactamase-producing Enterobacteriaceae. J Microbiol Immunol Infect. 2015;48(3):269-75.

27. Denisuik AJ, Lagacé-Wiens PRS, Pitout JD, Mulvey MR, Simner PJ, Tailor F, et al. Molecular epidemiology of extended-spectrum ß-lactamase-, AmpC ß-lactamase- and carbapenemase-producing Escherichia coli and Klebsiella pneumoniae isolated from Canadian hospitals over a 5 year period: CANWARD 2007-11. J Antimicrob Chemother. 2013;68 Suppl 1:i57-65.

28. Medina-Polo J, Arrébola-Pajares A, Pérez-Cadavid S, Benítez-Sala R, Sopeña-Sutil R, Lara-Isla A, et al. Extended-spectrum beta-lactamase-producing bacteria in a urology ward: epidemiology, risk factors and antimicrobial susceptibility patterns. Urol Int. 2015;95(3):288-92.

29. Bhusal Y, Mihu CN, Tarrand JJ, Rolston KV. Incidence of fluoroquinolone-resistant and extended-spectrum ß-lactamase-producing Escherichia coli at a comprehensive cancer center in the United States. Chemotherapy. 2011;57(4):335-8.

30. Belete MA. Bacterial profile and ESBL screening of urinary tract infection among asymptomatic and symptomatic pregnant women attending antenatal care of northeastern Ethiopia region. Infect Drug Resist. 2020;13:2579-92.

31. Malcolm W, Fletcher E, Kavanagh K, Deshpande A, Wiuff C, Marwick C, et al. Risk factors for resistance and MDR in community urine isolates: Population-level analysis using the NHS Scotland Infection Intelligence Platform. J Antimicrob Chemother. 2018;73(1):223-30.

32. Ayukekbong JA, Ntemgwa M, Atabe AN. The threat of antimicrobial resistance in developing countries: causes and control strategies. Antimicrob Resist Infect Control. 2017;6:47.